HDGF and PRKCA upregulation is associated with a poor prognosis in patients with lung adenocarcinoma

HDGF and PRKCA upregulation is associated with a poor prognosis in patients with lung adenocarcinoma
复制标题

HDGF 和 PRKCA 上调与肺腺癌患者预后不良相关

DOI:
10.3892/ol.2019.10812
复制
发表时间:
2019-11-01
期刊:
影响因子:
2.9
通讯作者:
Fang, Weiyi
Fang, Weiyi
中科院分区:
医学4区
文献类型:
--
作者:
Jiang, Honghong;Fu, Qiaofen;Fang, Weiyi

文献摘要

被引文献

相似文献

肺腺癌是肺癌最常见的组织学亚型。本研究的目的是评估肝癌衍生生长因子(HDGF)和蛋白激酶C α(PRKCA)在肺腺癌(LADC)中的表达,并确定这两种蛋白的联合表达与LADC患者临床病理特征之间的关系。通过GEO数据库分析评估HDGF和PRKCA mRNA的表达,并使用组织芯片通过免疫组织化学检测HDGF和PRKCA蛋白水平。与正常样本相比,在LADC组织中观察到高HDGF和PRKCA表达,并且HDGF和PRKCA表达增加与AJCC临床分期、肿瘤分类、淋巴结分类和淋巴结转移相关。GEO数据库分析显示LADC组织中HDGF mRNA和PRKCA mRNA之间无显著差异。然而,高PRKCA蛋白表达与高HDGF蛋白表达相关,高HDGF和PRKCA表达的患者的总体生存率低于两种蛋白低表达水平的患者。本研究的结果表明,HDGF和PRKCA的上调可能是肺腺癌进展的不利因素。
Lung adenocarcinoma is the most common histologic subtype of lung cancer. The aim of the present study was to assess the expression of hepatoma-derived growth factor (HDGF) and protein kinase C alpha (PRKCA) in lung adenocarcinoma (LADC), and to determine the association between the combined expression of these two proteins and clinicopathological characteristics of patients with LADC. The expression of HDGF and PRKCA mRNA was assessed by GEO database analysis, and HDGF and PRKCA protein levels were examined by immunohistochemistry using a tissue microarray. High HDGF and PRKCA expression was observed in LADC tissue compared to normal samples, and increased HDGF and PRKCA expression was associated with AJCC clinical stage, tumor classification, node classification, and lymph node metastasis. GEO database analysis revealed no significant differences between HDGF mRNA and PRKCA mRNA in LADC tissue. However, high PRKCA protein expression was associated with high HDGF protein expression, and patients with high HDGF and PRKCA expression exhibited poorer overall survival rates than patients with low expression levels of the two proteins. The results of the present study suggest that upregulation of both HDGF and PRKCA may be an unfavourable factor for lung adenocarcinoma progression.